TGFB1 and COVID-19: Conversely, the pro-fibrotic factor and anti-inflammatory TGF-β was statistically decreased in non-surviving patients, which is a significant finding due to the consideration of TGF-β blockade as a potential treatment in COVID-19 patients [34].